Sabbagh Marwan N, Schäuble Barbara, Anand Keshav, Richards Danielle, Murayama Shigeo, Akatsu Hiroyasu, Takao Masaki, Rowe Christopher C, Masters Colin L, Barthel Henryk, Gertz Hermann-Josef, Peters Oliver, Rasgon Natalie, Jovalekic Aleksandar, Sabri Osama, Schulz-Schaeffer Walter J, Seibyl John
Alzheimer's and Memory Disorders Division, Barrow Neurological Institute, Phoenix, AZ, USA.
Formerly Piramal Imaging GmbH, Berlin, Germany.
J Alzheimers Dis. 2017;56(2):441-446. doi: 10.3233/JAD-160821.
Of 57 individuals diagnosed with Alzheimer's disease (AD) in a phase III study, 13 (23%) had amyloid-β (Aβ) levels on postmortem histopathology that did not explain the dementia. Based on postmortem histopathology, a wide range of different non-AD conditions was identified, including frontotemporal dementia, hippocampal sclerosis, and dementia with Lewy bodies. Of the histopathologically Aβ negative scored cases ante-mortem Florbetaben PET scans were classified as negative for Aβ in 11 patients based on visual analysis and in all 12 quantifiable cases based on composite standardized uptake value ratios. Thus, florbetaben PET can assist physicians in the differential diagnosis of neurodegenerative disorders by reliably excluding Aβ pathology.
在一项III期研究中被诊断为阿尔茨海默病（AD）的57名个体中，13名（23%）在死后组织病理学检查中的淀粉样β蛋白（Aβ）水平无法解释其痴呆症状。基于死后组织病理学检查，发现了一系列不同的非AD病症，包括额颞叶痴呆、海马硬化和路易体痴呆。在组织病理学检查中Aβ阴性评分的病例中，根据视觉分析，11例患者生前的氟代贝他班PET扫描被分类为Aβ阴性，在所有12例可量化病例中，根据复合标准化摄取值比率也为Aβ阴性。因此，氟代贝他班PET可以通过可靠地排除Aβ病理学来帮助医生对神经退行性疾病进行鉴别诊断。
